Unique nanofabrication of antigens and adjuvants that effectively induces protective antibody and T cell responses

T rapid formulation of antigens and adjuvants in precisely defined size, shape, and composition is now possible with the nanotechnology platform called PRINTTM. This technology has been used to effectively co-delivery polysaccharides and bacterial proteins for encapsulated bacteria such as pneumococcus in virtual conjugates in which specific chemical conjugation is avoided. In the absence of added adjuvants both ELISA and opsonic immune responses equivalent or superior to the licensed Prevnar vaccine have been generated in both mice and rabbits. In addition, cellular responses, including IL-17 and IFN-γ, have been generated to specific pneumococcal proteins. Additional work using viral and protozoal antigens in conjunction with various TLR adjuvants have been used to demonstrate single dose responses to these antigens and the importance of formulating the adjuvant in the same particle as the antigen. PRINT offers a unique particle fabrication in a continuous manufacturing platform for rational design that can be adopted to provide vaccine solutions for multiple pathogens.